Are patients with schizophrenia treated less with second-line glucose-lowering drugs for type 2 diabetes? Response

被引：0
|
作者：
Bennett, Melanie E. [1 ]
Calkins, Monica E. [2 ,3 ]
Dickerson, Faith [4 ]
Kreyenbuhl, Julie [1 ]
Medoff, Deborah [1 ]
机构：
[1] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD USA
[2] Univ Penn, Perelman Sch Med, Penn Early Intervent Ctr PE HeadsUp, Dept Psychiat,Neurodev & Psychosis Sect, Philadelphia, PA USA
[3] Univ Penn, Perelman Sch Med, Dept Psychiat, Neurodev & Psychosis Sect, Philadelphia, PA USA
[4] Sheppard Pratt, Dept Psychol, Baltimore, MD USA
来源：
SCHIZOPHRENIA RESEARCH | 2024年 / 270卷
关键词：
D O I：
10.1016/j.schres.2024.06.012
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：235 / 236
页数：2
相关论文
共 50 条
  • [21] Glucose-lowering medicines for type 2 diabetes
    Davoren, Peter
    AUSTRALIAN FAMILY PHYSICIAN, 2015, 44 (05) : 272 - 276
  • [22] Risk of cardiovascular events in type 2 diabetes patients initiating second-line therapy with glucose lowering drugs: A population-based analysis
    Moura, Cristiano S.
    Elharram, Malik
    Abrahamowicz, Michal
    Bernatsky, Sasha
    Behlouli, Hassan
    Raparelli, Valeria
    Pilote, Louise
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 484 - 484
  • [23] New glucose-lowering drugs for reducing cardiovascular risk in patients with type 2 diabetes mellitus
    Gorgojo-Martinez, J. J.
    HIPERTENSION Y RIESGO VASCULAR, 2019, 36 (03): : 145 - 161
  • [24] Concomitant use of benzodiazepines and oral glucose-lowering drugs in patients with type-2 diabetes
    Fornero, Agostina
    Bertoldo, Pamela
    Dumont, Nilda
    FARMACEUTICOS COMUNITARIOS, 2018, 10 (01): : 41 - 46
  • [25] Personalized Approach in Cardiovascular Prevention for Women With Type 2 Diabetes Mellitus: Sex Differences in Second-Line Glucose Lowering Drugs
    Elharram, Malik
    Raparelli, Valeria
    Moura, Cristiano
    Abrahamowicz, Michal
    Bernatsky, Sasha
    Behlouli, Hassan
    Pilote, Louise
    CIRCULATION, 2018, 138
  • [26] Perioperative Management of Oral Glucose-lowering Drugs in the Patient with Type 2 Diabetes
    Preiser, Jean-Charles
    Provenzano, Bruna
    Mongkolpun, Wasineeart
    Halenarova, Katarina
    Cnop, Miriam
    ANESTHESIOLOGY, 2020, 133 (02) : 430 - 438
  • [27] Glucose-Lowering Drugs and Risk of COPD Exacerbations in Adults with Type 2 Diabetes
    Ray, Avik
    Paik, Julie M.
    Feldman, William B.
    Sreedhara, Sushama Kattinakere
    Wexler, Deborah J.
    Patorno, Elisabetta
    DIABETES, 2024, 73
  • [28] Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
    Holman, Rury R.
    Sourij, Harald
    Califf, Robert M.
    LANCET, 2014, 383 (9933): : 2008 - 2017
  • [29] Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes REPLY
    Kalyani, Rita R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (07): : 671 - 672
  • [30] Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes
    Gerstein, Hertzel C.
    Shah, Reema
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2018, 47 (01) : 97 - +
12345